Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLYC NASDAQ:PTGX NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLYCGlycoMimetics$0.16$13.48$15.15▼$28.77$10.13M1.6229,886 shsN/APTGXProtagonist Therapeutics$99.36+0.5%$99.40$42.85▼$107.84$6.36B1.89673,182 shs504,964 shsXOMAXOMA Royalty$41.89+1.5%$33.03$22.29▼$42.81$492M0.9412,816 shs111,717 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLYCGlycoMimetics0.00%0.00%0.00%+1.29%-99.35%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%XOMAXOMA Royalty-0.75%+0.85%+19.40%+66.09%+68.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLYCGlycoMimetics$0.16$13.48$15.15▼$28.77$10.13M1.6229,886 shsN/APTGXProtagonist Therapeutics$99.36+0.5%$99.40$42.85▼$107.84$6.36B1.89673,182 shs504,964 shsXOMAXOMA Royalty$41.89+1.5%$33.03$22.29▼$42.81$492M0.9412,816 shs111,717 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLYCGlycoMimetics0.00%0.00%0.00%+1.29%-99.35%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%XOMAXOMA Royalty-0.75%+0.85%+19.40%+66.09%+68.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLYCGlycoMimetics 0.00N/AN/AN/APTGXProtagonist Therapeutics 2.80Moderate Buy$113.6914.42% UpsideXOMAXOMA Royalty 2.29Hold$53.7528.31% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, XOMA, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.004/30/2026XOMAXOMA Royalty HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$39.004/27/2026XOMAXOMA Royalty Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/14/2026PTGXProtagonist Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $121.004/8/2026XOMAXOMA Royalty Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/20/2026XOMAXOMA Royalty HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$97.003/19/2026PTGXProtagonist Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$107.00 ➝ $110.003/19/2026PTGXProtagonist Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$95.00 ➝ $106.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLYCGlycoMimetics$10K1,013.15N/AN/A$0.08 per share1.96PTGXProtagonist Therapeutics$46.02M138.85N/AN/A$10.19 per share9.75XOMAXOMA Royalty$52.15M9.57$0.58 per share72.42$6.77 per share6.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/AXOMAXOMA Royalty$31.71M$1.4628.6960.71N/A45.75%10.32%3.49%5/12/2026 (Estimated)Latest PTGX, XOMA, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026XOMAXOMA Royalty$0.19N/AN/AN/A$13.91 millionN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million3/18/2026Q4 2025XOMAXOMA Royalty-$0.04$0.12+$0.16$0.26$11.13 million$13.76 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLYCGlycoMimeticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLYCGlycoMimeticsN/A1.921.92PTGXProtagonist TherapeuticsN/A17.7612.71XOMAXOMA Royalty1.153.373.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLYCGlycoMimetics75.19%PTGXProtagonist Therapeutics98.63%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipGLYCGlycoMimetics8.70%PTGXProtagonist Therapeutics4.90%XOMAXOMA Royalty8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLYCGlycoMimetics5064.53 million58.90 millionNo DataPTGXProtagonist Therapeutics12064.31 million61.16 millionOptionableXOMAXOMA Royalty1011.92 million10.86 millionOptionablePTGX, XOMA, and GLYC HeadlinesRecent News About These CompaniesXOMA Royalty (XOMA) Projected to Post Earnings on TuesdayMay 5 at 12:34 PM | marketbeat.comXOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the ...April 28, 2026 | bakersfield.comBXOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMAApril 28, 2026 | tmcnet.comXOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?April 28, 2026 | zacks.comXOMA Royalty (NASDAQ:XOMA) Downgraded to Hold Rating by Lucid Cap MktsApril 28, 2026 | marketbeat.comRoyalty powerhouse: Ligand and Xoma unite in $739 million dealApril 28, 2026 | msn.com$XOMA stock is up 9% today. Here's what we see in our data.April 27, 2026 | quiverquant.comQALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationApril 27, 2026 | prnewswire.comLigand Bets On Royalty Growth With XOMA Buyout Worth Over $700 MillionApril 27, 2026 | benzinga.comXOMA Royalty (NASDAQ:XOMA) Shares Gap Up - Here's What HappenedApril 27, 2026 | marketbeat.comXOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On MondayApril 27, 2026 | benzinga.comLigand Pharma to Acquire XOMA, Expands Royalty PortfolioApril 27, 2026 | tipranks.comShareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public ShareholdersApril 27, 2026 | prnewswire.comXOMA Royalty to be Acquired by Ligand PharmaceuticalsApril 27, 2026 | tipranks.comXOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its ShareholdersApril 27, 2026 | businesswire.comLigand to acquire XOMA Royalty in $740M all-cash dealApril 27, 2026 | msn.comXoma Royalty Shares Edge Up Premarket on Report of Takeover by LigandApril 27, 2026 | marketwatch.comLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | markets.businessinsider.comLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | globenewswire.comLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?April 23, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, XOMA, and GLYC Company DescriptionsGlycoMimetics NASDAQ:GLYCGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Protagonist Therapeutics NASDAQ:PTGX$99.36 +0.51 (+0.52%) Closing price 04:00 PM EasternExtended Trading$99.36 +0.00 (+0.01%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.XOMA Royalty NASDAQ:XOMA$41.89 +0.60 (+1.45%) Closing price 04:00 PM EasternExtended Trading$41.89 0.00 (0.00%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
